Prabhu Rajagopalan

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (7)

• The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia
  Blood Neoplasia 2025 DOI: 10.1016/j.bneo.2025.100108
  +Save
• A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
  Investigational New Drugs 2024 DOI: 10.1007/s10637-024-01489-1
  +Save
• A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
  Blood advances 2024 DOI: 10.1182/bloodadvances.2024014633
  +Save
• Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
  British journal of haematology 2024 DOI: 10.1111/bjh.19419
  +Save
• A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 DOI: 10.1158/1078-0432.ccr-20-4185
  +Save
• First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 DOI: 10.1200/jco.19.02085
  +Save
• Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
  The Lancet. Oncology 2019 DOI: 10.1016/s1470-2045(19)30412-7
  +Save